Related Experiment Video
Updated: Apr 18, 2026
Measuring Bone Remodeling and Recreating the Tumor-Bone Microenvironment Using Calvaria Co-culture and Histomorphometry
Published on: March 14, 2020
A three-dimensional dynamic in vitro bone remodeling model reveals multicellular effects of anti-osteoporotic agents
Jun-Min Cai1, Yu-Xin Han1, Yu-Yao Mo1
1National Clinical Research Center for Endocrine and Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, China.
Abstract:
Anti-osteoporotic drugs are effective in reducing fracture risk, yet their long-term management is frequently associated with paradoxical skeletal complications, the cellular basis of which remains poorly defined. Bone remodeling is a continuous process that depends on functional coupling between osteoclast-mediated bone resorption and mesenchymal stem cell (MSC)-driven bone formation. Using a three-dimensional dynamic in vitro system that preserves osteoclast activity on bone surfaces, we investigated how anti-osteoporotic agents modulate osteoclast-MSC interactions. We found that zoledronic acid suppressed osteoclast maturation and resorptive activity, while concurrently inhibiting MSC migration and subsequent osteoblastic differentiation. In contrast, teriparatide enhanced MSC recruitment and osteogenic differentiation but also accelerated the maturation of multinucleated osteoclasts and bone resorption. These findings indicate that both anti-resorptive and anabolic therapies exert complex multicellular effects that extend beyond their classical lineage-specific actions, leading to altered coupling dynamics during bone remodeling. Our study provides cellular insight into drug-associated skeletal side effects and establishes a functional platform for evaluating the multicellular impact of osteoporosis therapies.
Insights
Osteoporosis drugs impact bone remodeling by affecting both bone-resorbing osteoclasts and bone-forming mesenchymal stem cells (MSCs). This study reveals complex cellular interactions influencing skeletal health during long-term drug management.
Area of Science:
- Bone Biology
- Cellular Interactions
- Pharmacology
Background:
- Osteoporosis therapies reduce fracture risk but can cause skeletal complications.
- Bone remodeling relies on coupled osteoclast resorption and mesenchymal stem cell (MSC)-driven formation.
- The cellular mechanisms behind drug-induced skeletal side effects are not well understood.
Purpose of the Study:
- To investigate how anti-osteoporotic drugs affect interactions between osteoclasts and MSCs.
- To elucidate the cellular basis of paradoxical skeletal complications associated with osteoporosis treatments.
Main Methods:
- Utilized a three-dimensional dynamic in vitro system to maintain osteoclast activity on bone.
- Examined the effects of zoledronic acid and teriparatide on osteoclast-MSC communication and function.
Main Results:
- Zoledronic acid inhibited osteoclast activity and MSC migration/osteoblastic differentiation.
- Teriparatide promoted MSC recruitment/osteogenic differentiation but accelerated osteoclast maturation and resorption.
- Both drug classes demonstrated complex multicellular effects beyond their primary targets.
Conclusions:
- Anti-osteoporotic therapies exert complex, multicellular effects impacting bone remodeling coupling.
- Understanding these drug-induced cellular interactions is crucial for managing skeletal side effects.
- The developed in vitro system provides a platform for evaluating the multicellular impact of osteoporosis therapies.
More Related Videos
08:53Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
11:47A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:31Bone Remodeling and Repair
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...